Our findings demonstrate that a simple six-colour flow cytometry panel targeting CD45, CD3, CD4, CD57, CCR7, and CD45RA could provide robust discrimination among healthy donors and patients at different stages of coronary artery disease (iCAD vs. ASCAD). This evidence concerns the gene CCR7 and coronary artery disorder.